These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 12594816)

  • 1. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
    Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
    Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
    Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
    Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
    Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population.
    Tran TN; Liu Y; Takagi M; Yamaguchi A; Fujii H
    J Oral Pathol Med; 2005 Mar; 34(3):150-6. PubMed ID: 15689228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.